» Articles » PMID: 31665774

A Multicenter Cost-of-Illness and Long-term Socioeconomic Follow-up Study in the Severe Typhoid Fever in Africa Program: Study Protocol

Abstract

Background: There are limited data on typhoid fever cost of illness (COI) and economic impact from Africa. Health economic data are essential for measuring the cost-effectiveness of vaccination or other disease control interventions. Here, we describe the protocol and methods for conducting the health economic studies under the Severe Typhoid Fever in Africa (SETA) program.

Methods: The SETA health economic studies will rely on the platform for SETA typhoid surveillance in 4 African countries-Burkina Faso, Ethiopia, Ghana, and Madagascar. A COI and long-term socioeconomic study (LT-SES) will be its components. The COI will be assessed among blood culture-positive typhoid fever cases, blood culture-negative clinically suspected cases (clinical cases), and typhoid fever cases with pathognomonic gastrointestinal perforations (special cases). Repeated surveys using pretested questionnaires will be used to measure out-of-pocket expenses, quality of life, and the long-term socioeconomic impact. The cost of resources consumed for diagnosis and treatment will be collected at health facilities.

Results: Results from these studies will be published in peer-reviewed journals and presented at scientific conferences to make the data available to the wider health economics and public health research communities.

Conclusions: The health economic data will be analyzed to estimate the average cost per case, the quality of life at different stages of illness, financial stress due to illness, and the burden on the family due to caregiving during illness. The data generated are expected to be used in economic analysis and policy making on typhoid control interventions in sub-Saharan Africa.

Citing Articles

The cost of typhoid illness in low- and middle-income countries, a scoping review of the literature.

Debellut F, Friedrich A, Baral R, Pecenka C, Mugisha E, Neuzil K PLoS One. 2024; 19(6):e0305692.

PMID: 38917139 PMC: 11198801. DOI: 10.1371/journal.pone.0305692.


Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics.

Haselbeck A, Tadesse B, Park J, Gibani M, Cruz Espinoza L, Abreu A Vaccines (Basel). 2021; 9(3).

PMID: 33808924 PMC: 8003794. DOI: 10.3390/vaccines9030281.


Methodological Considerations for Cost of Illness Studies of Enteric Fever.

Mejia N, Ramani E, Pallas S, Song D, Abimbola T, Mogasale V Clin Infect Dis. 2020; 71(Suppl 2):S111-S119.

PMID: 32725239 PMC: 7388717. DOI: 10.1093/cid/ciaa481.


The Severe Typhoid Fever in Africa Program Highlights the Need for Broad Deployment of Typhoid Conjugate Vaccines.

Carey M, Steele A Clin Infect Dis. 2019; 69(Suppl 6):S413-S416.

PMID: 31665775 PMC: 6821154. DOI: 10.1093/cid/ciz637.

References
1.
Poulos C, Riewpaiboon A, Stewart J, Clemens J, Guh S, Agtini M . Cost of illness due to typhoid fever in five Asian countries. Trop Med Int Health. 2011; 16(3):314-23. DOI: 10.1111/j.1365-3156.2010.02711.x. View

2.
Riewpaiboon A, Piatti M, Ley B, Deen J, Thriemer K, von Seidlein L . Cost of illness due to typhoid Fever in pemba, zanzibar, East Africa. J Health Popul Nutr. 2014; 32(3):377-85. PMC: 4221443. View

3.
Crump J, Luby S, Mintz E . The global burden of typhoid fever. Bull World Health Organ. 2004; 82(5):346-53. PMC: 2622843. View

4.
Jeon H, Pak G, Im J, Owusu-Dabo E, Adu-Sarkodie Y, Sow A . Determining the Best Immunization Strategy for Protecting African Children Against Invasive Salmonella Disease. Clin Infect Dis. 2018; 67(12):1824-1830. PMC: 6260167. DOI: 10.1093/cid/ciy386. View

5.
Ukwenya A, Ahmed A, Garba E . Progress in management of typhoid perforation. Ann Afr Med. 2011; 10(4):259-65. DOI: 10.4103/1596-3519.87040. View